Clinical Trial Update: Gilteritinib for the Treatment of ALK NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating gilteritinib for ALK-positive non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gilteritinib (gilteritinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Status: RECRUITING